Raymond James & Associates C4 Therapeutics, Inc. Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	BUY	$1.18 - $6.03 $11,332 - $57,912	9,604 Added 10.51%	100,984 $570,000
Q3 2023 Oct 24, 2023	BUY	$1.81 - $3.89 $12,934 - $27,797	7,146 Added 8.48%	91,380 $169,000
Q2 2023 Jul 25, 2023	BUY	$2.75 - $3.77 $58,113 - $79,667	21,132 Added 33.49%	84,234 $231,000
Q1 2023 Apr 14, 2023	BUY	$3.1 - $9.02 $1,689 - $4,915	545 Added 0.87%	63,102 $198,000
Q4 2022 Feb 08, 2023	SELL	$5.42 - $10.24 $4,742 - $8,960	-875 Reduced 1.38%	62,557 $369,000
Q3 2022 Oct 25, 2022	BUY	$8.03 - $12.77 $276,151 - $439,160	34,390 Added 118.41%	63,432 $556,000
Q2 2022 Aug 12, 2022	BUY	$5.06 - $26.46 $146,952 - $768,451	29,042 New	29,042 $219,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.